Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma

Cancer Cell

Volumn 32, Issue 3, 2017, Pages 295-309.e12

  Bosse, Kristopher R ^a,b   Raman, Pichai ^a   Zhu, Zhongyu ^c   Lane, Maria ^a   Martinez, Daniel ^a   Heitzeneder, Sabine ^d   Rathi, Komal S ^a   Kendsersky, Nathan M ^a   Randall, Michael ^a   Donovan, Laura ^e   Morrissy, Sorana ^e   Sussman, Robyn T ^a,b   Zhelev, Doncho V ^c   Feng, Yang ^c   Wang, Yanping ^c   Hwang, Jennifer ^c   Lopez, Gonzalo ^a   Harenza, Jo Lynne ^a   Wei, Jun S ^f   Pawel, Bruce ^a   Bhatti, Tricia ^a   Santi, Mariarita ^a   Ganguly, Arupa ^b   Khan, Javed ^f   Marra, Marco A ^g   Taylor, Michael D ^e   Dimitrov, Dimiter S ^c   Mackall, Crystal L ^d,h   Maris, John M ^a,b   more..

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody drug conjugate; glypican; immunotherapy; medulloblastoma; MYCN; neuroblastoma

Indexed keywords

ANTIBODY DRUG CONJUGATE; GLYPICAN; GLYPICAN 2; ONCOPROTEIN; UNCLASSIFIED DRUG; CANCER ANTIBODY; GPC2 PROTEIN, HUMAN; MESSENGER RNA; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA SEQUENCE; TRANSCRIPTION INITIATION; ANIMAL; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CHILD; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; PATHOLOGY; RISK FACTOR; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GLYPICANS; HUMANS; IMMUNOTHERAPY; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; N-MYC PROTO-ONCOGENE PROTEIN; NEUROBLASTOMA; ONCOGENE PROTEINS; RISK FACTORS; RNA, MESSENGER;

EID: 85030436231     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.08.003     Document Type: Article

References (40)

1. Bosse, K.R., Maris, J.M., Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122 (2016), 20–33.
2. Campeau, E., Ruhl, V.E., Rodier, F., Smith, C.L., Rahmberg, B.L., Fuss, J.O., Campisi, J., Yaswen, P., Cooper, P.K., Kaufman, P.D., A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One, 4, 2009, e6529.
3. Carpenter, E.L., Haglund, E.A., Mace, E.M., Deng, D., Martinez, D., Wood, A.C., Chow, A.K., Weiser, D.A., Belcastro, L.T., Winter, C., et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31 (2012), 4859–4867.
4. Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122 (2013), 3461–3472.
5. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
6. Filmus, J., Capurro, M., Rast, J., Glypicans. Genome Biol., 9, 2008, 224.
7. Gao, W., Tang, Z., Zhang, Y.F., Feng, M., Qian, M., Dimitrov, D.S., Ho, M., Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat. Commun., 6, 2015, 6536.
8. Griebel, T., Zacher, B., Ribeca, P., Raineri, E., Lacroix, V., Guigo, R., Sammeth, M., Modelling and simulating generic RNA-Seq experiments with the flux simulator. Nucleic Acids Res. 40 (2012), 10073–10083.
9. Harenza, J.L., Diamond, M.A., Adams, R.N., Song, M.M., Davidson, H.L., Hart, L.S., Dent, M.H., Fortina, P., Reynolds, C.P., Maris, J.M., Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci. Data, 4, 2017, 170033.
10. Hart, L.S., Rader, J., Raman, P., Batra, V., Russell, M.R., Tsang, M., Gagliardi, M., Chen, L., Martinez, D., Li, Y., et al. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin. Cancer Res. 23 (2017), 1785–1796.
11. Kim, M.S., Pinto, S.M., Getnet, D., Nirujogi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Kelkar, D.S., Isserlin, R., Jain, S., et al. A draft map of the human proteome. Nature 509 (2014), 575–581.
12. Kocak, H., Ackermann, S., Hero, B., Kahlert, Y., Oberthuer, A., Juraeva, D., Roels, F., Theissen, J., Westermann, F., Deubzer, H., et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis., 4, 2013, e586.
13. Kunkele, A., Taraseviciute, A., Finn, L.S., Johnson, A.J., Berger, C., Finney, O., Chang, C.A., Rolczynski, L.S., Brown, C., Mgebroff, S., et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin. Cancer Res. 23 (2017), 466–477.
14. Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, 2009, R25.
15. Law, C.W., Chen, Y., Shi, W., Smyth, G.K., voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol., 15, 2014, R29.
16. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
17. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., The sequence alignment/map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
18. Mantaj, J., Jackson, P.J., Rahman, K.M., Thurston, D.E., From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew. Chem. Int. Ed. 56 (2017), 462–488.
19. Maris, J.M., Recent advances in neuroblastoma. N. Engl. J. Med. 362 (2010), 2202–2211.
20. Matas-Rico, E., van Veen, M., Leyton-Puig, D., van den Berg, J., Koster, J., Kedziora, K.M., Molenaar, B., Weerts, M.J., de Rink, I., Medema, R.H., et al. Glycerophosphodiesterase GDE2 promotes neuroblastoma differentiation through glypican release and is a marker of clinical outcome. Cancer Cell 30 (2016), 548–562.
21. Northcott, P.A., Shih, D.J., Peacock, J., Garzia, L., Morrissy, A.S., Zichner, T., Stutz, A.M., Korshunov, A., Reimand, J., Schumacher, S.E., et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488 (2012), 49–56.
22. Orentas, R.J., Yang, J.J., Wen, X., Wei, J.S., Mackall, C.L., Khan, J., Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front. Oncol., 2, 2012, 194.
23. Pugh, T.J., Morozova, O., Attiyeh, E.F., Asgharzadeh, S., Wei, J.S., Auclair, D., Carter, S.L., Cibulskis, K., Hanna, M., Kiezun, A., et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45 (2013), 279–284.
24. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
25. Saunders, L.R., Bankovich, A.J., Anderson, W.C., Aujay, M.A., Bheddah, S., Black, K., Desai, R., Escarpe, P.A., Hampl, J., Laysang, A., et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med., 7, 2015, 302ra136.
26. Seaman, S., Zhu, Z., Saha, S., Zhang, X.M., Yang, M.Y., Hilton, M.B., Morris, K., Szot, C., Morris, H., Swing, D.A., et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31 (2017), 501–515.e8.
27. Shen, Y., Yue, F., McCleary, D.F., Ye, Z., Edsall, L., Kuan, S., Wagner, U., Dixon, J., Lee, L., Lobanenkov, V.V., Ren, B., A map of the cis-regulatory sequences in the mouse genome. Nature 488 (2012), 116–120.
28. Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M.R., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5 (2015), 1282–1295.
29. Stallings, R.L., Howard, J., Dunlop, A., Mullarkey, M., McDermott, M., Breatnach, F., O'Meara, A., Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?. Cancer Genet. Cytogenet. 140 (2003), 133–137.
30. Suzuki, M., Cheung, N.K., Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets 19 (2015), 349–362.
31. Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. Proteomics. Tissue-based map of the human proteome. Science, 347, 2015, 1260419.
32. Valentijn, L.J., Koppen, A., van Asperen, R., Root, H.A., Haneveld, F., Versteeg, R., Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 65 (2005), 3136–3145.
33. Valentijn, L.J., Koster, J., Haneveld, F., Aissa, R.A., van Sluis, P., Broekmans, M.E., Molenaar, J.J., van Nes, J., Versteeg, R., Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 109 (2012), 19190–19195.
34. Vivian, J., Rao, A., Nothaft, F.A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A.D., Musselman-Brown, A., et al. Rapid and efficient analysis of 20,000 RNA-seq samples with toil. bioRxiv, 2016, 062497.
35. Wang, X., Dubuc, A.M., Ramaswamy, V., Mack, S., Gendoo, D.M., Remke, M., Wu, X., Garzia, L., Luu, B., Cavalli, F., et al. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol. 129 (2015), 449–457.
36. Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363 (2010), 1324–1334.
37. Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Thierry-Mieg, D., Wang, J., Furlanello, C., Devanarayan, V., Cheng, J., Deng, Y., et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol., 16, 2015, 133.
38. Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., Liu, X.S., Model-based analysis of ChIP-Seq (MACS). Genome Biol., 9, 2008, R137.
39. Zhu, Z., Dimitrov, A.S., Bossart, K.N., Crameri, G., Bishop, K.A., Choudhry, V., Mungall, B.A., Feng, Y.R., Choudhary, A., Zhang, M.Y., et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80 (2006), 891–899.
40. Zhu, Z., Ramakrishnan, B., Li, J., Wang, Y., Feng, Y., Prabakaran, P., Colantonio, S., Dyba, M.A., Qasba, P.K., Dimitrov, D.S., Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 6 (2014), 1190–1200.